Atea Pharmaceuticals, Inc.
AVIRAtea Pharmaceuticals is a late-stage clinical biopharmaceutical company focused on discovering and developing oral antiviral therapies for serious viral diseases.
Table of contents
Earnings
Next report
Aug 6, 2026 (In 3 weeks)Competitors
By market cap
By revenue growth
Profile
Atea Pharmaceuticals is a late-stage clinical biopharmaceutical company focused on discovering and developing oral antiviral therapies for serious viral diseases. The company leverages a proprietary nucleos(t)ide platform to target single-stranded RNA viruses, specifically addressing significant unmet needs in hepatitis C and hepatitis E. Their core value proposition lies in creating potent, well-tolerated direct-acting antivirals that simplify treatment regimens and improve patient outcomes.
A late-stage clinical developer aiming to disrupt the standard of care in HCV with a protease inhibitor-free, short-duration regimen and introduce the first direct-acting antiviral for HEV.
Questions, answered.
- What is Atea Pharmaceuticals, Inc.'s market cap?
- Atea Pharmaceuticals, Inc. (AVIR) has a market capitalization of $392.9M and trades on NASDAQ.
- Who are Atea Pharmaceuticals, Inc.'s competitors?
- Atea Pharmaceuticals, Inc.'s key competitors include Gilead Sciences, Inc., AbbVie, Inc., Merck & Co., Inc., and others. These companies compete in similar markets and product categories.
- Who does Atea Pharmaceuticals, Inc. partner with?
- Atea Pharmaceuticals, Inc.'s notable partners include Merck & Co., Inc., Gilead Sciences, Inc..
- What subsidiaries does Atea Pharmaceuticals, Inc. have?
- Atea Pharmaceuticals, Inc.'s subsidiaries include Atea Pharmaceuticals Securities Corporation.
- Where is Atea Pharmaceuticals, Inc. headquartered?
- Atea Pharmaceuticals, Inc. is headquartered in United States of America and employs approximately 74 people. It has been publicly traded since 2020.